<DOC>
	<DOCNO>NCT00931632</DOCNO>
	<brief_summary>This phase 3 , multi-center , double blind , placebo-controlled , randomized clinical trial attempt demonstrate preterm infant require mechanical ventilation and/or positive pressure support point day 5 14 birth may benefit treatment iNO .</brief_summary>
	<brief_title>Inhaled Nitric Oxide ( INO ) Prevention Bronchopulmonary Dysplasia ( BPD ) Preterm Infants</brief_title>
	<detailed_description>Multi-center , double blind , placebo-controlled , randomized clinical trial . Infants meet enrollment criterion point day 5 14 birth randomize inhaled NO start 20 ppm , match placebo , mean blind INOvent® delivery device . All infant receive 24 day therapy , follow dose reduction schedule . Infants extubated 24 day continue therapy via nasal continuous positive airway pressure ( CPAP ) nasal cannula complete 24 day ' therapy . The primary outcome measure survival without BPD 36 week gestational age use physiologic assessment BPD .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Preterm infant : 1 . 500 1250 gram birth 2 . &lt; 30 week gestational age 3 . 5 14 day age ( inclusive ) time entry 4 . Requiring mechanical ventilation infant ≤ 800 gram , positive pressure support ( include CPAP ) respiratory insufficiency day 5 14 day age ( inclusive ) 1 . Preterm infant lifethreatening anomaly ( cranial , cardiac , thoracic , chromosomal ) congenital diaphragmatic hernia lung hypoplasia , subject receive complete intensive care 2 . Preterm infant bilateral Grade 4 intraventricular hemorrhage ( IVH ) 3 . Subjects dependent right leave shunt maintain systemic circulation 4 . Preterm infant receive prior iNO therapy 5 . Use another investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bronchopulmonary Dysplasia , BPD</keyword>
</DOC>